An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

Carfilzomib is a next-generation proteasome inhibitor that selectively and irreversibly binds to its target. In clinical studies, carfilzomib has shown efficacy in patients with relapsed and/or refractory multiple myeloma (MM) and has demonstrated a tolerable safety profile. In this phase 2, open-la...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Br J Haematol
Autores principales: Vij, Ravi, Siegel, David S., Jagannath, Sundar, Jakubowiak, Andrzej J., Stewart, A. Keith, McDonagh, Kevin, Bahlis, Nizar, Belch, Andrew, Kunkel, Lori A., Wear, Sandra, Wong, Alvin F., Wang, Michael
Formato: Artigo
Lenguaje:Inglês
Publicado: 2012
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5818209/
https://ncbi.nlm.nih.gov/pubmed/22845873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2012.09232.x
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares